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The identity and unique capacity of cancer stem cells (CSC) to drive tumor growth and
resistance have been challenged in brain tumors. Here we report that cells expressing CSC-
associated cell membrane markers in Glioblastoma (GBM) do not represent a clonal entity
defined by distinct functional properties and transcriptomic profiles, but rather a plastic state
that most cancer cells can adopt. We show that phenotypic heterogeneity arises from non-
hierarchical, reversible state transitions, instructed by the microenvironment and is pre-
dictable by mathematical modeling. Although functional stem cell properties were similar
in vitro, accelerated reconstitution of heterogeneity provides a growth advantage in vivo,
suggesting that tumorigenic potential is linked to intrinsic plasticity rather than CSC multi-
potency. The capacity of any given cancer cell to reconstitute tumor heterogeneity cautions
against therapies targeting CSC-associated membrane epitopes. Instead inherent cancer cell
plasticity emerges as a novel relevant target for treatment.
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G lioblastoma (GBM) displays extensive cellular hetero-geneity which represents a major obstacle for effectivetreatment. Similar to other cancers, tumor progression
has been proposed to rely on cancer stem cells (CSC), responsible
for tumor recurrence and resistance to therapy. CSCs are pos-
tulated to display diverse stem cell properties and to be highly
tumorigenic in experimental models in vivo1. The model predicts
that CSCs reside at the apex of a hierarchical organization and
recreate intra-tumoral phenotypic heterogeneity by generating
differentiated progeny. Recent single-cell transcriptomic analysis
revealed stem cell-signatures to be associated with the most
proliferative cells in low grade gliomas, where stemness increases
with tumor grade2,3. Such an organization was less clear in GBM,
which displayed a continuum of stemness profiles anti-correlated
with cell-cycle genes4. Although very informative, such data
describe marker expression at a given snapshot in time and do
not consider the dynamic functional properties of tumor cells
displaying different phenotypes. Similarly, genetic barcoding
techniques suggesting a proliferative hierarchy in GBM5 cannot
address phenotypic heterogeneity and evolution of phenotypic
states over time.
Identification of CSCs is largely based on the expression of cell
membrane antigens, which are amenable to targeted therapy6. In
GBM many studies rely on cell surface markers such as CD133,
CD15/SSEA, CD44, or A2B5 for CSC isolation7–10, yet no single
marker is able to define a universal GBM CSC population11. The
identity of GBM CSCs is still unresolved and, although widely
used, there is controversy whether marker-expressing cells fulfill
the functional criteria of bona fide CSCs12 and whether CSCs
represent a quiescent or a proliferative subpopulation. In this
context, functional assays combined with marker expression are
indispensable for the validation of CSC properties1.
The hierarchical CSC model has been challenged by growing
evidence suggesting that CSCs may not constitute a defined cel-
lular entity, but rather a cellular state adapting to micro-
environmental cues13. Initial reports on GBM suggested that only
CSC-marker positive cells were able to form tumors7,9, while
later studies reported either no difference in tumorigenic
potential8,14,15 or both fractions being tumorigenic, but with
different potency11,16,17. Although generally marker positive cells
were shown to be multipotent, multipotency of marker negative
cells was rarely addressed. Several GBM studies, however, showed
that marker positive cells can be derived from the negative frac-
tion and regain the initial heterogeneity11,14,17,18 supporting
strong tumor plasticity in recreating intra-tumoral phenotypic
heterogeneity. Numerous data supporting the concept of
plasticity19,20 point to a role of the microenvironment in shaping
the phenotype toward spatial and temporal heterogeneity21.
Indeed, GBM cells expressing stem cell markers are often
attributed to specific tumor niches22–26. It still remains unclear
whether the microenvironment selects for survival of specific
CSCs or whether tumor cells adapt within new microenviron-
ments. Intriguingly, recent data further showed that GBM CSCs
alone carry limited tumorigenic potential, and reciprocal crosstalk
with tumor cells representing more differentiated phenotypes
creates supportive niches and promotes tumor growth27,28. These
results point toward a key role of tumor cell plasticity and intra-
tumoral phenotypic heterogeneity in shaping tumor progression.
Although several mathematical approaches aimed to model the
creation and maintenance of CSC and non-CSC states in devel-
oping tumors based on intrinsic cellular parameters, modeling
tumor plasticity in the context of changing spatial and temporal
microenvironments remains challenging21,29,30.
Here we asked whether cancer cells expressing CSC-associated
cell membrane markers are a defined entity at the apex of a
hierarchical organization or whether they represent a phenotypic
state that cells can reversibly acquire in response to environ-
mental cues. Similar to patient biopsies, we observe CSC markers
to be heterogeneously expressed in patient-derived GBM xeno-
grafts and stem-like cell cultures. We find that all GBM cell
subpopulations that carry stem cell properties, are tumorigenic
and are able to adapt to various environmental changes. Our data
show that cells expressing stem cell markers do not represent a
clonal entity defined by distinct functional properties and
transcriptomic signatures, but rather a cellular state that is
determined by environmental conditions. Such states are non-
hierarchical, reversible and occur via stochastic state transitions of
existing populations, striving toward an equilibrium within a
given microenvironment. While all subpopulations survive and
are capable of phenotype adjustment, differences exist in the
adaptation speed resulting in different tumor growth rates in vivo.
This indicates that the outcome and interpretation of functional
assays depend on dynamic processes and endpoint of analysis.
Our data provide evidence that stem cell-associated phenotypic
heterogeneity in GBM is a result of intrinsic cancer cell plasticity,
which has important implications for the design of treatment
strategies. If the CSC state is an inducible and transient state, then
targeting only a small subpopulation of cancer cells will be inef-
fective, instead the dynamic processes will need to be tackled.
Results
Inter- and intra-tumor heterogeneity of putative CSC marker.
So far no universal CSC marker has been identified in GBM. In an
attempt to identify cell surface markers shared by most GBM
patients, we compared the expression of 10 commonly used CSC-
associated markers in the TCGA patient cohort. This showed
variable expression levels across tumors (Fig. 1a) and little asso-
ciation with known genetic or epigenetic alterations (Supple-
mentary Fig. 1A–C). No significant correlations were detected
between marker genes (Fig. 1b). As expected31, several markers
were enriched in previously defined transcriptional subgroups
(Supplementary Fig. 1D, E).
It is well established that gene expression does not necessarily
correspond to epitope presentation and CSCs may represent
varying abundance across individual patient tumors32. Moreover,
bulk analysis of transcriptional profiles in GBM patients
represents mean values of tumor and stroma33 and cell membrane
epitopes can be present in both compartments34. Therefore, we
applied multicolor flow cytometry on fresh GBM tissue isolated
from 11 patient-derived orthotopic xenografts (PDOXs). PDOXs
were established from GBM with different genetic background35
in eGFP-expressing mice36, which allowed us to discriminate
tumor and stromal cells and phenotype the tumor compartment
in an unbiased manner (Supplementary Fig. 2A, B). Similar to
gene expression analysis, epitope presentation of 12 CSC markers
was highly variable between tumors (Fig. 1c, Supplementary
Fig. 3A, B). CD90 and CD29 were strongly positive in most GBM,
whereas CD24 and CD195 were largely absent. In most cases,
marker expression was relatively homogeneous within one GBM,
while only 4/12 markers (CD133, CD44, CD15, and A2B5)
showed relevant intra-tumoral heterogeneity (Fig. 1c, Supplemen-
tary Fig. 3B), which would be expected from a bona fide CSC
marker. We have previously described different microenviron-
mental landscapes in GBM PDOX models, either displaying a
purely infiltrative phenotype or showing extensive necrosis,
hypoxia, and vascular leakage35. However, no link between
marker expression profiles and histopathological tumor pheno-
types was observed here (Supplementary Fig. 3).
Genetically distinct clones adapt marker expression in vivo. We
have previously shown that intra-tumor heterogeneity in GBM is
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09853-z




















































































































































































































































































































































































































Fig. 1 CSC-associated heterogeneity in GBM. a Inter-patient heterogeneity at the gene expression level for a panel of CSC-associated markers. See also
Supplementary Fig. 1. b Pearson analysis did not reveal any significant correlation. c Flow cytometric analysis of tumor cells in GBM PDOXs. Percentage of
positive cells (black gate) is indicated vs. negative control and vs. high expressing cells (red gate). See Supplementary Fig. 2 for gating strategy and
Supplementary Fig. 3 for more examples. dMarker expression profiles in the genetically heterogeneous PDOX T16 (all tumor (black), pseudodiploid (blue),
and aneuploid (red) clones). Separately implanted pseudodiploid (blue) and aneuploid clones (red) adapted the CSC-associated profiles in the xenograft
(right). eMulticolor phenotyping. Representative ImageStream data shown for NCH644. Right panel: color code for 16 subpopulations applied in all figures.
f Distribution of subpopulations in seven patient-derived GBM cultures (mean %, error bars ommitted for visualization purpose). g Distribution of CSC-
associated markers and Ki67 proliferating cells in 3D spheres (scale bar= 100 µm)
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also present at the ploidy level and that CSC-associated marker
expression is distributed throughout genetically different clones37,
as shown here, e.g., for CD133 and A2B5 (Fig. 1d). FACS-purified
pseudodiploid and aneuploid cells independently gave rise to
tumors in the mouse brain, with the aneuploid clone being more
tumorigenic37. Here we assessed whether the differential marker
profile was retained in individual ploidy clones or whether clones
adapted their marker expression upon in vivo growth. Interest-
ingly, both clones changed marker expression in vivo, i.e., pseu-
dodiploid clones retained a heterogeneous A2B5 profile and
increased CD133, while aneuploid clones significantly increased
A2B5 epitope presentation (Fig. 1d), indicating that CSC-
associated marker expression in vivo is not a defined property
of a genetic clone and that tumor cells change marker expression
following clonal selection, most probably reflecting an adaptation
to the new microenvironment.
Heterogeneity in GBM stem-like cultures. In order to correlate
marker presentation with CSC functional properties, we turned to
patient-derived GBM cultures. Although in vitro models carry
inherent drawbacks, patient-derived cultures represent the best
model to address the full spectrum of stemness properties and are
commonly applied for CSC studies in human GBMs38. This is not
possible in our PDOX models due to limited proliferation
in vitro. Although short-term cultures derived from GBM xeno-
grafts can be useful27, in our experience these cultures are
genetically unstable (similar to long term cultures) and during
first passages contain genetically divergent clones with different
ploidy levels (Supplementary Fig. 2F). To avoid any bias in the
outcome of functional studies37 we focused our analysis on seven
GBM stem-like cultures, which are genetically stable, show a
similar genetic profile as patient tumors and retain stable CSC
marker expression over passages. Similar to patient biopsies and
PDOXs, GBM cultures displayed remarkable inter-patient het-
erogeneity of CSC markers (Supplementary Fig. 3B), which was
stable across cell passaging. CD133, CD44, CD15, and
A2B5 showed again the strongest heterogeneity within each GBM
culture. Focusing on these four markers, we performed multicolor
flow cytometry to discriminate 16 subpopulations, which were
applied to define phenotypic heterogeneity throughout the study
(labeled P1–P16; Fig. 1e, f, Supplementary Fig. 2C, D). Some
cultures contained a limited number of predominant sub-
populations, while 4/7 cultures contained a substantial amount of
all 16 subpopulations. The heterogeneity was present at the single
sphere level without a particular localization pattern, nor a link
with proliferative cells more prominent at sphere edges (Fig. 1g).
All subpopulations were proliferating, although some
CD133−CD44− cells (P9–P12) contained less cells in S/G2/M
(Supplementary Fig. 4A). This may reflect the fluctuation of
CD133 across the cell cycle39. Thus, patient-derived GBM cul-
tures recapitulate the intra-tumoral phenotypic heterogeneity of
CSC marker expression observed in patient biopsies and PDOXs.
All GBM subpopulations carry stem cell properties in vitro. To
investigate stem cell properties of different phenotypic states we
combined FACS-based purification with functional assays. Self-
renewal, proliferation, and multipotency tests were performed on
the 16 subpopulations of highly heterogeneous GBM cultures
(Fig. 2a). Importantly, all FACS-sorted subpopulations were
subjected to the same culture conditions, giving them equal
chance to display stem cell properties. This is in contrast to other
studies that apply different growth conditions on marker positive
(serum-free) and negative (serum-containing) subpopulations
(e.g., refs. 25,27), thereby introducing a bias induced by environ-
mental factors. We found that all FACS-sorted subpopulations
were able to self-renew over multiple passages with no significant
differences between each other (Fig. 2b). No dilution of differ-
entiated counterparts and progenitors was observed as indicated
by similar sphere size. All subpopulations proliferated indefinitely
at a similar rate (Fig. 2c). This indicated that phenotypically
heterogeneous GBM cells have similar stem cell properties
in vitro, suggesting a lack of hierarchical organization.
GBM subpopulations undergo stochastic state transitions. We
next performed multipotency tests by multicolor phenotyping for
FACS-purified subpopulations over time to reveal which sub-
populations were responsible for creating the phenotypic het-
erogeneity. Surprisingly, none of the subpopulations maintained
its original phenotype in time. Alluvial plots in Fig. 2d represent
the dynamic evolution of phenotypic heterogeneity, where the
proportions of phenotypic states are ordered from the most
prominent states at the top to the least prominent states at the
bottom at each time point (see Supplementary Fig. 5A for an
alternative display of the data in column charts, where phenotypic
states are displayed in the same order, P1–P16, at each time point
and Supplementary Data 2A for statistics). All subpopulations
were able to recreate the phenotypic heterogeneity consisting of
different phenotypic states, indicating that none of them repre-
sented a unipotent differentiated phenotype as expected in a one-
way hierarchical model. This was also true for clones derived
from single cells (Supplementary Fig. 5B). Most phenotypic states
were already reestablished after 20 days (D20), although the
adaptation was dynamic over time and varied between sub-
populations (Fig. 2d). However, at day 70 (D70), all 16 sub-
populations were reconstituted in each sample suggesting a
tendency toward the original phenotypic equilibrium. The mul-
tipotency of different subpopulations was confirmed in additional
GBM cultures (Supplementary Fig. 4B).
To quantify state transitions in time between the different
phenotypes and predict the time of equilibrium, we applied
CellTrans, a stochastic compartment model based on the Markov
chain40, which represents an established tool for assessment of
state transitions based on FACS data41. We assumed that the
phenotypic state compositions could be determined by two main
processes: (i) stochastic state transitions due to cellular plasticity
and (ii) different proliferation rates reflecting selection. Since all
subpopulations proliferated at a similar rate (Fig. 2c), this
parameter could be excluded from the modeling. We acknowl-
edge that cell–cell interactions are likely to play a role in state
transitions. However, since marker heterogeneity was present at
the single sphere level without a specific distribution pattern
(Fig. 1g) and in the absence of known quantifiable data about
inter-cellular interactions, we neglected spatial aspects to keep the
model tractable and focused on key processes. The model
estimated the occurrence of 175 of 240 possible direct state
transitions (Fig. 2e, Supplementary Fig. 5C). The estimated
transition matrix appeared irreducible with no bottlenecks, i.e.,
each phenotype could transit to other states either directly or
through intermediate steps. No hierarchies or sub-hierarchies
were detected between the phenotypes (Krackhardt hierarchy
score= 0). Moreover, transitions between positive and negative
states of one marker were independent of the other markers
(Supplementary Table 1A). Interestingly, the theoretical equili-
brium was very similar to the original composition (Fig. 2f), even
though this parameter had not been taken into account for the
modeling.
We next tested the validity of the model by comparing the
predicted values with experimental data by designing two
combinations of subpopulations (mix A and B, time= 0)
predicted to reach the equilibrium in 39 days. The FACS-sorted
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admixtures reverted to the original equilibrium at the predicted
time point (Fig. 2g, Supplementary Data 1A). Interestingly,
although the model predicted that all subpopulations reach the
same equilibrium, they varied in the time needed (Fig. 2h), with
P2 and P12 showing the fastest transitions. In conclusion, all
subpopulations retain full capacity to generate other phenotypic
states. Despite differences in pace, heterogeneity is recapitulated
in time from each phenotypic state in a non-hierarchical manner.
Hypoxia induces phenotypic adaptation. We then asked to what
extent the phenotypic heterogeneity is dependent on the micro-
environment and whether changing conditions leads to selection
or adaptation of phenotypic states. We first focused on hypoxia, a
hallmark of GBM, representing a clinically relevant micro-
environment. Although it has been reported that hypoxia enri-
ches for CSCs42,43, it is not clear whether such phenotypic shifts
result from a selection of an existing CSC subpopulation or from
phenotypic adaptation. Although GBM cells in vivo may be
subjected to an oxygen gradient depending on their spatial
location, we opted to recapitulate severe hypoxia with oxygen
levels < 0.5% O2. This condition corresponds to the most hypoxic
area surrounding the necrotic tumor zone, previously associated
with the CSC niche. We have minimized the bias linked to
acidification of culture media by regular monitoring of pH levels.
Concordant with previous reports, exposure to hypoxia led to a
clear shift in phenotype (Fig. 3a, Supplementary Fig. 4C, Sup-
plementary Data 1B, C). For example, hypoxic NCH644 cells
were more positive for CD133, CD44, and A2B5, whereas CD15
was decreased. In particular, subpopulations P5 and P7 were
enriched, whereas several others (e.g., P2, P10) were reduced.
Changes were not always gradual in time, suggesting the occur-
rence of indirect state transitions before reaching a new hypoxia-
specific equilibrium. We have previously shown that low oxygen
leads to growth inhibition, activation of glycolysis44, and autop-
hagy45, although NCH644 displayed less dead/apoptotic cells
compared with NCH421k (Supplementary Fig. 4F). The pheno-
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Fig. 2 GBM subpopulations undergo state transitions in a non-hierarchical manner. a Experimental setup of FACS sorting and functional analysis performed
on 16 subpopulations (NCH644). See Supplementary Fig. 2E for gating strategy. b Self-renewal test, including sphere formation (mean+ /− SEM) and
sphere diameter (Box limits indicate the 25th and 75th percentiles and center lines show the medians as determined by R software; whiskers represent the
extreme low and high observed values, unless those are above 1.5 times interquartile range (IQR)—thereby whiskers are limited to 1.5 IQR. All outlying data
points are represented by dots). Bulk cells were used as control (CTR). No statistical difference observed, except for P11 passages 1 vs. 2 and 1 vs. 3
(*p-value≤ 0.05, Kruskal–Wallis test). c Proliferation test (mean doubling time+ /− SEM). No statistical difference observed. dMultipotency test. Marker
expression over time: FACS-sorting day 0 (D0) and re-phenotyping after 20 (D20), 30 (D30), and 70 (D70) days in culture. The order of subpopulations
in alluvial plots is based on highest to lowest percentage at each time point. See an alternative representation in Supplementary Fig. 5A for column chart
and Supplementary Data 2A for statistics (color code in Fig. 1e). e Markov modeling of state transitions between 16 subpopulations. Arrows represent
predicted direct state transitions between subpopulations, thickness of lines corresponds to transition probabilities. See Supplementary Fig. 5C for
transition matrix. f Proportions of subpopulations predicted in equilibrium state is similar to initial culture. g Validation of Markov modeling. FACS-sorted
admixtures (time 0) were re-phenotyped at the predicted equilibrium time (39 days) showing the accuracy of the mathematical model. See Supplementary
Data 1A for statistics. h Predicted time to reach equilibrium for each subpopulation
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PROM1 and CD44 already after 12 h of hypoxia suggesting fast
adaptation (Supplementary Table 2).
To test whether the changes were a result of selection or
phenotypic adaptation we next performed functional assays
under hypoxia (Fig. 2a). Again, all subpopulations self-renewed
(Fig. 3b) and proliferated (Fig. 3c). Certain subpopulations
differed in self-renewal potential during initial passages (Supple-
mentary Data 4). P10, P12, and P14 showed low clonogenic
potential at the first passage, which was in accordance with their
reduction in long-term hypoxia (Fig. 3a), pointing to a possible
partial selection at early time points. These differences were later
lost, indicating efficient adaptation. Although single cells gave rise
to smaller spheres compared with normoxia, hypoxic spheres did
not differ in size between each other (Fig. 3b). The decreased self-
renewal did not correlate with the proliferation index as only two
subpopulations statistically differed from each other (Fig. 3c). All
subpopulations proliferated indefinitely, though at a decreased
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hypoxia and their proliferation index suggests a strong role of
phenotypic adaptation to a changing environment.
Modeling GBM state transitions in hypoxia. To model pheno-
typic adaptation to hypoxia, we analyzed FACS-sorted sub-
populations after 60 days in hypoxia. All subpopulations created a
phenotypic distribution resembling the original hypoxic cultures,
rather than the normoxic equilibrium, e.g., CD133 levels were
increased in all subpopulations regardless of their initial state
(Fig. 3d, Supplementary Data 2B). Change toward a hypoxia-
specific equilibrium of CD133 positive and negative cells was
confirmed in other GBM cultures (Supplementary Fig. 4D). Sta-
tistical differences were still observed at 60 days, suggesting that
the equilibrium had not been reached yet. Nevertheless, all sub-
populations recreated a phenotypic heterogeneity in hypoxia.
This was also true for clones reformed from single cells following
the self-renewal test (Supplementary Fig. 5D, Supplementary
Data 3B).
We have further applied Markov chain modeling to assess state
transitions in hypoxia. Since all cells were subjected to severe
hypoxia in vitro and subpopulations proliferated at similar rates,
we applied the same modeling strategy as for normoxia, excluding
the spatial aspect of microenvironmental cues. Markov chain
modeling revealed that, although direct state transitions were
more restricted compared with normoxia (103/240; Fig. 3e,
Supplementary Fig. 5E), all subpopulations could transit to other
states except to P10. This was in accordance with the very low
proportion of P10 observed in hypoxia (Fig. 3a) and its low self-
renewal potential at initial passage (Fig. 3b). Notably, P10 survived
hypoxia and could transform to other states, preferentially to P3.
Subpopulations enriched in hypoxia (e.g., P5, P7) could be
formed from numerous phenotypic states (≥9). The transition
matrix appeared reducible with one transient state (P10, i.e., no
phenotype can transit into P10 and P10 is depleted from the
hypoxic equilibrium), but no absorbing state (i.e., exit from this
state is not possible). Most populations needed > 250 days to
reach hypoxic equilibrium (Fig. 3f), compared with 92 days for
the bulk culture. Of note, the subpopulations enriched in hypoxia
(e.g., P5, P7) did not carry an advantage to reach equilibrium
faster, rather, the subpopulations not enriched (P2, P9, and P12)
were most adaptive. Interestingly, they also belonged to the fastest
adapting subpopulations in normoxia (Fig. 2h). Altogether these
results show that the phenotypic shift in hypoxia occurs through
adaptation of existing cells. Only a very limited hierarchy
(Krackhardt hierarchy score= 0.125, Supplementary Table 1B)
was observed. Although we cannot exclude a partial selection for
certain phenotypic states, all subpopulations survived hypoxia
and re-adapted to reach a hypoxia-specific equilibrium.
Induced phenotypic adaptations are reversible. We further
tested marker expression in more complex environments,
including combined exposure to extracellular matrix, differ-
entiation agents (FBS, ATRA), and hypoxia. Upon differentiation
cells underwent morphological changes both in normoxia
(Fig. 4a) and hypoxia (Supplementary Fig. 6A). Although
expression of neuronal (β-III-tubulin) and astrocytic (GFAP)
markers increased, CSC-associated intracellular markers (Nestin,
Vimentin) remained expressed, suggesting an incomplete differ-
entiation process (Fig. 4b; Supplementary Fig. 6B). In normoxia,
differentiation resulted in a strong shift toward CD133− and
CD44+ subpopulations (P13–P16), although CD133−CD44−
cells (P11) were also enriched (Fig. 4c, Supplementary Data 1D).
Although similar changes were observed in hypoxia, the pheno-
typic shift was clearly the result of two environmental pressures,
i.e., a decrease of CD133+ cells upon differentiation was com-
pensated by increased CD133 in hypoxia (Fig. 4c). Similar data
were obtained for another GBM model, which lost the pre-
dominance of the P2 subpopulation both in normoxia and
hypoxia (Supplementary Fig. 6D, Supplementary Data 1D).
We next assessed the phenotypic heterogeneity upon returning
to normoxic 3D conditions. Regardless of the differentiation
status and oxygen level, GBM cells regrew as 3D spheres and
regained the expression of intracellular stem cell markers
(Supplementary Fig. 6C). This was accompanied by a partial
regain of the initial cell membrane marker phenotype at day 14
(Fig. 4c, Supplementary Fig. 6D, Supplementary Data 1D, E).
Markov modeling predicted a longer time to fully revert to
normoxic equilibrium from differentiated states (75 and 84 days
from Diff_N and Diff_H conditions, respectively). In summary,
GBM cells undergo specific reversible phenotypic changes shaped
concomitantly by various microenvironmental cues.
Reversible adaptation of CSC-associated phenotypes in vivo.
We next asked whether the reversible phenotypic adaptation
occurs in vivo. All five implanted GBM cultures adapted their
phenotype to the brain environment (Fig. 4d; Supplementary
Fig. 6E, F, Supplementary Data 1F, G) with a strong tendency
toward the enrichment of CD133−CD44− cells (P9–P12) and
depletion of CD133+ CD44+ (P5–P8) and CD133−CD44+
(P13–P16) cells. These changes were also detected at the tran-
script level (Supplementary Table 2) and differed from the
equilibria observed in hypoxic and differentiation conditions
in vitro, suggesting the impact of additional factors in the com-
plex in vivo microenvironment. This was also true for the
intracellular stem cell and differentiation markers (Fig. 4e, Sup-
plementary Fig. 6G). Again, the phenotypic change in vivo was
reversible and xenografted tumor cells regained the hetero-
geneous profile when returned to in vitro conditions (Fig. 4d,
Supplementary Fig. 6E, Supplementary Data 1F, G). Xenografted
cells were recultured for a time period equivalent to the tumor
development time, at which point the phenotypic equilibrium of
the original cultures was not yet reached, in accordance with
mathematical modeling.
Fig. 3 Adaptation of GBM subpopulations to hypoxia. a Distribution of subpopulations in hypoxia (H). Normoxia (N) is shown as control (CTR) and hypoxia
(H) at 16 h, 48 h, 7 days, and 60 days. Data shown for NCH644, additional cultures in Supplementary Fig. 4C. See statistics in Supplementary Data 1B,
color code in Fig. 1e. b Self-renewal test of 16 subpopulations in hypoxia, including sphere formation (mean+ /− SEM) and sphere diameter (Box limits
indicate the 25th and 75th percentiles and center lines show the medians as determined by R software; whiskers represent the extreme low and high
observed values, unless those are above 1.5 times interquartile range (IQR)—thereby whiskers are limited to 1.5 IQR. All outlying data points are
represented by dots). Bulk cells were used as control (CTR). Statistical differences within the same subpopulations are shown (*p-value≤ 0.05,
Kruskal–Wallis test, see Supplementary Data 4B for statistics). c Proliferation test in hypoxia (mean doubling time+ /− SEM). Bulk cells were used as
control (CTR). Statistical difference was only found between P7 and P13 (mixed linear model). d Distribution of 16 subpopulations at day 0 (left) and after
60 days in hypoxia (right) (see Supplementary Data 2B for statistics). e Markov modeling of state transitions in hypoxia. Arrows represent direct state
transitions between subpopulations, thickness of lines corresponds to transition probabilities. See Supplementary Fig. 5E for transition matrix. f Predicted
time needed to reach equilibrium for each subpopulation in hypoxia
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Accelerated tumor growth in vivo of more plastic states. To rule
out a negative selection against certain subpopulations, we
implanted individual subpopulations directly after FACS sorting,
focusing on four phenotypic states: P6 and P15 strongly depleted
in vivo; P11 strongly enriched in vivo (Fig. 4d); and P2 the most
plastic state in normoxia and hypoxia (Figs. 2h and 3f), partially
depleted in vivo. While all subpopulations formed tumors, we
observed a difference in mouse survival (Fig. 4f). Only mice
bearing P2 developed tumors as fast as the parental cells, whereas
P6, P11, and P15 grew slower. Interestingly, all subpopulations
changed phenotype in vivo resembling the original in vivo
equilibrium (Fig. 4g, Supplementary Data 1H). This shows that
the subpopulations were able to undergo state transitions in vivo
toward an in vivo environment-specific equilibrium. Differences
in tumor development in vivo are linked to the time required by
each subpopulation to reach the final environment-specific het-
erogeneity. This suggests that high tumorigenic potential may be
linked to the fast adapting cells with enhanced intra-tumoral
phenotypic heterogeneity. Our data further support recent find-
ings27, suggesting a key role of intra-tumoral heterogeneity and
reciprocal crosstalk of phenotypically different tumor cells in
creating tumor growth promoting niches.
Phenotypic states display a similar transcriptome. To correlate
intra-tumoral heterogeneity at the phenotypic and transcriptomic
level we applied single cell sequencing using the Drop-seq
method46 on three PDOXs and two GBM cultures. Although a
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Fig. 4 Reversible phenotypic changes. a Examples of adherent GBM cells in stem cell (Undiff_N) or differentiation (Diff_N) conditions in normoxia. See
Supplementary Fig. 6A for hypoxia (scale bar= 200 µm). b Flow cytometric analysis of intracellular markers in control 3D sphere cultures (CTR),
differentiation (Diff) conditions. N normoxia, H hypoxia. Black lines discriminate between negative and positive cells (mean+ /− SEM, n= 3). Dotted line
indicates mode expression in control cells. See also Supplementary Fig. 6B, C. c Distribution of subpopulations under different environmental conditions,
phenotyping performed after 14 days of change (left) and 14 days after reverting to control culture (right). See Supplementary Data 1D for statistics and
Supplementary Fig. 6D for more examples. d Distribution of subpopulations in xenografted NCH644 tumors in vivo (X) and after regrowth in vitro (De-X).
Normoxia cultures are shown as control (CTR). See Supplementary Data 1F for statistics and Supplementary Fig. 6E, F for more examples. e Flow
cytometric analysis of intracellular markers. Black lines discriminate between negative and positive cells (mean+ /− SEM, n= 3). Dotted line indicate
mode expression in control cells. f Kaplan–Meier survival curves of xenotransplanted mice. Subpopulations P2, P6, P11, and P15 were implanted directly
after FACS. FACS-sorted bulk cells were used as control (CTR) (*p-value≤ 0.05; **p-value≤ 0.01, long-rank test). g Distribution of subpopulations in
xenografted tumors. For each subpopulation, day of implant and day of mouse sacrifice are presented. See Supplementary Data 1H for statistics
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each tumor, we did not detect distinct sub-clusters and each
tumor showed similar transcriptional cell-to-cell variability
(Fig. 5a, cell-to-cell correlation coefficients: 0.72–0.86). If detec-
ted, transcripts coding for cell membrane markers were uniformly
distributed across the tumor (Fig. 5b, Supplementary Fig. 7A) and
their expression was not linked to the cell cycle (Fig. 5c). This was
also true for intracellular stemness (NES, VIM) and differentia-
tion markers (GFAP) (Supplementary Fig. 7A).
As transcripts coding for cell membrane markers were
generally detected at low levels (Supplementary Fig. 7B), we were
not able to discriminate 16 phenotypic states based on mRNA
expression. Therefore, we performed Drop-seq on two subpopu-
lations: P2 (representing the most adaptive phenotypic state in
normoxia, hypoxia and in vivo) and P6 (representing cells
positive for all stem cell-associated markers but being less
adaptive). Interestingly, the two phenotypic states displayed
similar transcriptomic profiles to each other and to the
heterogeneous parental culture (Fig. 5d, Supplementary Fig. 7C,
D), suggesting no profound transcriptomic differences between
subpopulations carrying different levels of plasticity. The lack of
distinct cell subpopulations at the transcriptomic level further
questions a strong hierarchical organization of subpopulations
defined by cell membrane markers and suggests subtler molecular
differences between different phenotypic states grown under the
same culture conditions.
Limited impact of chemotherapy on CSC-associated pheno-
type. We next asked whether marker expression was affected by
treatment. Although GBM resistance to Temozolomide (TMZ), a
DNA alkylator, has been suggested to be conferred by CSCs
selectively surviving treatment47, conflicting data exist with
regard to CSC chemoresistance in GBM48,49. In order to mimic
clinically relevant drug doses (5–50 µM) we applied a low TMZ
concentration (i.e., IC20 of corresponding cell line). This only led
to minor changes of subpopulations in NCH644 TMZ-resistant
cells even after long-term treatment (Fig. 6a, Supplementary
Data 1I). Minor changes were also observed in NCH421k TMZ-
sensitive cultures, with an increase in heterogeneity at day 7
(Fig. 6a, Supplementary Data 1J). Similarly to hypoxia, the
changes in time were not always gradual suggesting adaptation
via intermediate states. Since a sublethal dose was applied, cell
death could be ruled out as a significant factor in phenotypic
selection. Furthermore, no major changes were detected at the
transcript level after short-term exposure (24 h) to high dose of






































































Fig. 5 Distinct phenotypic states carry similar transcriptome. a Overall gene expression relationship between single cells of three GBM PDOXs and two
GBM cultures. Patient-derived cells are color coded. b Expression of marker genes in NCH644 (expression gradient color coded). See Supplementary Fig. 7
for more examples. c Estimation of cell cycle state of individual cells on the basis of relative expression of G1/S and G2/M gene sets. d Gene expression
relationship between subpopulations P2 and P6 and the original heterogeneous GBM cultures (Control= CTR). Each sample is color coded. See
Supplementary Fig. 7C, D for further analysis
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09853-z ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1787 | https://doi.org/10.1038/s41467-019-09853-z | www.nature.com/naturecommunications 9
changes in GBM upon long term TMZ treatment in vivo
(Fig. 6b). This was confirmed in paired patient samples of
recurrent GBMs, where no transcriptomic differences in marker
expression were observed after treatment (Fig. 6c). Similarly, we
did not detect changes in marker expression following anti-
angiogenic treatment with bevacizumab, an antibody against
vascular endothelial growth factor (VEGF) (Supplementary
Fig. 6H)50. Overall, these data indicate that subpopulations of
cells expressing CSC-associated markers are not selectively enri-
ched by current treatment approaches, questioning their rele-
vance as a resistance mechanism.
Discussion
Functional heterogeneity of cancer cells is determined not only by
the genetic makeup but also by non-genetic programs such as
stemness features and interactions with the microenvironment.
Although it is widely appreciated that cancer cells with stem cell
properties exist within solid tumors, the clinical significance of
CSC properties is still an open question. We find that phenotypic
heterogeneity based on cell membrane markers in GBM is a
dynamic process of reversible state transitions. All GBM sub-
populations displayed stem cell properties and were tumorigenic,
supporting the notion that cancer cells are highly plastic in their
response to microenvironmental cues. Despite the absence of a
phenotypic hierarchy, we noted a functional difference reflected
in tumor development time in vivo, which appeared to be cor-
related with the ability to reconstitute phenotypic heterogeneity.
These data advise against targeting a small subpopulation of CSCs
defined by cell membrane markers and highlight the importance
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Fig. 6 Phenotypic heterogeneity in GBM after treatment. a Distribution of subpopulations upon TMZ treatment. Cultures were treated with TMZ for 16 h,
2 days, and 7 days. See Supplementary Data 1I, J for statistics. b Phenotyping of tumor cells revealed no changes of marker expression upon TMZ treatment
in vivo (PDOX T16). c Comparative gene expression analysis of genes coding for four cell membrane markers in paired primary and recurrent IDHwt GBM
samples (n= 78) based on RNA-seq data from the RecuR cohort33. Box limits indicate the 25th and 75th percentiles and center lines show the medians as
determined by R software; whiskers represent the extreme low and high observed values, unless those are above 1.5 times interquartile range (IQR)—
thereby whiskers are limited to 1.5 IQR. All outlying data points are represented by dots. No significant statistical differences were detected (two sided
paired t-test)
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Our study is in line with previous reports demonstrating strong
inter-patient heterogeneity and the difficulty to identify bona fide
CSC markers. Only a subset of markers fulfilled the CSC criteria
of heterogeneous expression within tumors. We show that the
expression of CSC markers in vivo is not intrinsic to specific
genetic clones, but is an adaptation process in response to
external cues. In GBM cultures the cell membrane marker-
associated phenotype was flexible, all subpopulations carried
stemness properties and reconstituted heterogeneity. Importantly,
we show that the phenotypic heterogeneity could also be recre-
ated by single cells of different phenotypic profiles. Although
lineage tracing is a powerful technique to follow the development
of individual clones and their proliferative capacities5, these
techniques are currently not applicable for functional studies in
combination with multicolor cell membrane phenotyping, limit-
ing our study to reconstitution of clones from single FACS-sorted
cells. We further show that phenotypic heterogeneity is created
via stochastic non-hierarchical state transitions between pheno-
typic states, in line with previous observations where CD133
negative GBM cells were able to revert to the CD133+ phenotype
in vivo14. None of the phenotypic states was unipotent and
irreversible in the tested microenvironments, including normoxia,
severe hypoxia and in vivo. GBM cells also reverted from a more
differentiated state, in line with the disappointing effects of dif-
ferentiation therapy38. Despite potential differences between solid
tumors, our data are in agreement with reports from other can-
cers, including breast and melanoma51–53. While we cannot
exclude a partial selection upon environmental pressure, we did
not observe the complete eradication of subpopulations under
any conditions, including drug treatment. Moreover, all popula-
tions adapted toward the most optimal equilibrium, suggesting
that state transitions are tightly regulated to reach the best fitted
balance. This is in contrast to previous reports suggesting targeted
selection of CSCs and the loss of differentiation capacities in
hypoxia42,43. For example, we find that all subpopulations,
regardless of their initial phenotype, increased CD133 expression
in hypoxia in a reversible manner, arguing against a targeted
selection of CD133+ cells. CD133 was also activated in initially
negative cultures (Supplementary Fig. 4E) and also CD133 high
hypoxic cells were able to undergo aberrant differentiation. In line
with previous reports54, we observe fast and reversible activation
of marker expression at the transcriptomic level under hypoxic
conditions. Although further studies are needed to identify the
factors leading to phenotypic adaptation in vivo in the spatial and
temporal context, stromal cells and the metabolic landscape of the
brain are likely to play a key role1. Macrophage/microglia24,
pH26, and glucose levels25 have been proposed to be implicated in
phenotypic shifts, with the two latter parameters being intimately
associated with the hypoxic niche. Reversibility to CSC-like states
is also possible via activation of defined transcriptional factors55.
Although all cells carried stem cell properties and were
tumorigenic, we observed differences in the speed of plasticity,
which correlated to tumor development in vivo. A shorter tumor
development time was linked to a higher level of plasticity,
reaching a favorable environment-specific heterogeneity more
quickly. Our data are in agreement with a recent study, showing
that reciprocal crosstalk of GBM cells displaying different phe-
notypes promotes tumor growth27. We propose that an increased
tumorigenic potential of CSC-like states may be a consequence of
an accelerated adaptation to the microenvironment, rather than a
unique multipotency per se. This adds a novel criteria to the CSC-
like state and may explain some of the reported controversies in
functional assays: while all cells are plastic, some adapt faster to
new environments in vivo, leading to differences between in vitro
self-renewal and in vivo transplantation assays. As highlighted
previously56, the outcome of these assays strongly depends on
experimental conditions (e.g., culture conditions of purified
subpopulations and implanted cell number) and endpoint
determination (i.e., the time allowed for tumor development in
mice).
Why some states appear more plastic than others is currently
not clear. In addition to the genetic status, epigenetic flexibility
regulating transcriptional networks may play a role57. Phenoty-
pically distinct subpopulations retained a largely similar tran-
scriptome, suggesting more subtle differences within GBM
compared with, e.g., breast cancer51,53. This is in line with recent
single cell RNA-seq data, revealing a continuous stem cell sig-
nature4. It remains to be seen if this is confirmed in other patient-
derived cells and if more differences are present between less
abundant coding and non-coding RNA transcripts, which are
below the sensitivity of the Drop-seq method. More important
transcriptomic differences could be expected if tumor cells are
acutely extracted from in vivo tumors, where cells may reside in
different niches. Although not addressed in this study, the
changes of epitope presentation upon environmental impacts can
arise from different mechanisms, including mRNA and protein
expression changes, changes in protein localization and con-
formation; and/or epitope posttranslational modifications influ-
encing epitope recognition17,32.
Although initial reports suggested targeted selection of putative
CSCs upon treatment47,58, later studies could not find evidence of
CSC enrichment following chemotherapy48,49. In some studies,
GBM CSCs were more resistant to radiation compared with their
non-CSC conterparts, however, non-CSCs also remained rela-
tively radioresistant59 and acquired similar properties to CSCs
upon exogenous treatment60. Here, we did not detect major
phenotypic changes neither upon long-term treatment in vitro
with clinically relevant TMZ doses, nor upon short-term treat-
ment with a high dose. No major changes were observed also
in vivo after treatment with TMZ or bevacizumab, arguing
against a selective survival of CSC subpopulations or a role in
intrinsic resistance. Although high TMZ doses over a prolonged
period of time could potentially lead to a stronger selective
pressure and the selection of certain phenotypic states, this
condition is unlikely to be achieved in patients with the current
treatment protocol (therapeutically achievable dose: 5–50 µM61).
Of note, we have previously shown that neither TMZ, nor bev-
acizumab activates the stem cell-associated efflux property,
defined as the side population phenotype, in GBM cells34,62. In
summary, these data highlight the limitations of therapeutic
strategies targeting cell membrane marker-defined CSCs,
including CSC-directed immunotherapies63.
Phenotypic plasticity is a powerful mechanism for overcoming
selective pressures both during tumor development and adapta-
tion to changing microenvironments, e.g., nutrient supply, oxy-
gen level or treatment. Studing the dynamic feedback of tumor
cells and their in vivo niche will require the development of
complex mathematical models that explicitly include such inter-
actions. In keeping, advanced mathematical simulations of state
transitions following combinatorial treatment predicted the sur-
vival of the most plastic clones64. In breast cancer, it was shown
that the tumorigenic potential was lost by inhibiting the transition
from CD44-low toward CD44-high cells53. Elucidating state
transition programs and mechanisms driving cellular plasticity
will be essential to overcome current therapeutic limitations.
Methods
TCGA gene expression analysis. The gene expression pattern across glioma
patients was investigated using The Cancer Genome Atlas (TCGA) cohort via
GlioVis data portal65 and Cbioportal66. Expression value corresponds to median-
centered RNA-seq data, DNA methylation data were from a merged dataset on
25,978 probes shared by the HM27 and HM450 platforms analysis (#syn2486658)),
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genomic copy number alterations were from PanCan12 Genom (https://www.
synapse.org/). Putative copy number calls on 563 cases determined using GISTIC
2,0–2= homozygous deletion; −1= hemizygous deletion, 0= neutral, 1= gain,
2= high level amplification. Mutation data are from whole-exome sequencing of
291 tumors. Heatmaps were generated using Gitools software67. Group comparison
was performed using Mann–Whitney–Wilcoxon, and Benjamini Hochberg mul-
tiple test correction was applied (at p= 0.05, Mann–Whitney–Wilcoxon null
hypothesis: correlation= 0). Gene expression data analysis of longitudal cohort of
IDHwt GBMs33 was performed through http://recur.bioinfo.cnio.es/ with RNA-seq
(n= 78 per group) and AffymetrixU133A (n= 23 per group) datasets. Statistical
analysis was performed by two-sided paired t-test.
Patient-derived orthotopic xenografts (PDOXs). GBM samples were collected at
Centre Hospitalier in Luxembourg (Neurosurgical Department) or Haukeland
University Hospital (Bergen, Norway) from patients having given informed con-
sent, and with approval from the local ethics committees (National Ethics Com-
mittee for Research (CNER), Luxembourg, local ethics committee Haukeland
University Hospital, Bergen). All biopsies were from IDHwt GBMs. Organotypic
GBM spheroids were derived from patient samples and cultured in DMEM
medium, 10% FBS, 2 mM L-Glutamine, 0.4 mM NEAA, and 100 Uml−1 Pen-Strep;
Lonza in agar pre-coated flasks for 7–10 days. Spheroids were implanted in the
brain of eGFP-expressing Nod/Scid mice34,36. Animals were sacrificed at the
appearance of neurological symptoms and/or weight loss. PDOX models are
available from the corresponding author or via EuroPDX consortium (https://www.
europdx.eu/) on reasonable request.
The GBM patient-derived xenograft (PDOX T16, n= 5) was used for
Temozolomide (TMZ) treatment (unmethylated MGMT promoter, in vitro IC50
for TMZ ≈ 1 mM), receiving intraperitoneal injections of TMZ (Sigma 200 mg kg−1
in 10% DMSO) three times a week, starting 2 weeks after spheroid implantation.
For anti-angiogenic treatment, mice (PDOX P3, n= 5) received weekly
intraperitoneal injections of bevacizumab (Avastin, Roche; 20 mg kg−1 in saline),
starting 3 weeks after spheroid implantation50. Control animals received injections
of 10% DMSO or saline, respectively. The handling of the animals and the surgical
procedures were performed in accordance with the regulations of the European
Directive on animal experimentation (2010/63/EU), i.e., the experimental protocols
were approved by the local ethics committee (Animal Welfare Structure of the
Luxembourg Institute of Health) and by the Luxembourg Ministries of Agriculture
and of Health.
Glioblastoma patient-derived cultures. The GBM serum-free cultures NCH421k,
NCH660h, NCH465, NCH601, and NCH644, were provided by Dr Christel Herold-
Mende (Department of Neurosurgery, University of Heidelberg)35. GBM cells were
derived immediately after dissociation of primary patient tumor and culture in 3D
serum-free conditions. NCH421k, NCH660h, NCH465, and NCH601 were cultured
as non-adherent spheres in DMEM-F12 medium (Lonza) containing 1× BIT100
(Provitro), 2 mM L-Glutamine, 30 Uml−1 Pen-Step, 1 Uml−1 Heparin (Sigma), 20
ng ml−1 bFGF (Miltenyi, 130-093-841), and 20 ng ml−1 EGF (Provitro,
1325950500). NCH644 grew in Neurobasal® base medium (Life Technologies)
supplemented with 1× B27 (Life Technologies) 2 mM L-Glutamine, 30 Uml−1
Pen-Step, 1 Uml−1 Heparin (Sigma), 20 ng ml−1 bFGF (Miltenyi, 130-093-841),
and 20 ng ml−1 EGF (Provitro, 1325950500). The GBM cultures TB101 and TB107,
kindly provided by Dr. Håkan Hedman (Umeå University, Sweden), were cultured
in DMEM-F12 medium (Lonza) containing 1× B27 and 1× N2 supplements
(Provitro), 2 mM L-Glutamine, 30 Uml−1 Pen-Step, 1 Uml−1 Heparin (Sigma),
20 ng ml−1 bFGF (Miltenyi, 130-093-841), and 20 ng ml−1 EGF (Provitro,
1325950500). P13NS short term cultures were derived from PDOX P13 and cul-
tured in serum-free medium based on Neurobasal® base medium as described
above. U87 cells (obtained from ATCC, HTB-14) were cultured as monolayers in
DMEM containing 10% FBS, 2 mM L-Glutamine, and 100 Uml ml−1 Pen-Strep
(Lonza). Classical normoxic cultures were performed at 37 °C under 5% CO2
atmospheric oxygen. pH of the cultures was monitored with phenol red. GBM
cultures were tested for cell membrane marker expression profiles over several
passages with no major changes observed over time. Similarly no difference in
marker distribution was observed within the individual 3D spheres of different
sizes (average sphere size 300 µm). Small changes in the composition of serum-free
media had no impact on the cell membrane marker profiles. Cell lines were reg-
ularly tested for mycoplasma contamination. Cell lines were authenticated by DNA
profiling using SNP-based multiplex approach and compared with the other
continuous cell lines in the DSMZ database. SNP profiles were unique.
Hypoxia, differentiation, and TMZ treatment. In vitro TMZ (Sigma) treatment
was performed at sublethal doses (200 µM for NCH644 and 25 µM for NCH421k)
for indicated time points (16 h, 2 days, and 7 days). NCH421k have a methylated
MGMT promoter and a low IC50 (272 µM). NCH644 have an unmethylated
MGMT promoter (IC50 ≈ 227 mM). The experiment was repeated independently
four times (nB= 4) with three technical replicates per subpopulation (nT= 3).
TMZ was refreshed every 3 days. During hypoxia cells were maintained at 0.5% O2
in a hypoxic incubator (Galaxy 48R incubator, New Brunswick) for the indicated
time points (16 h, 48 h, 7 days, and 60 days). Experiments were repeated
independently three times (nB= 3) with three technical replicates per subpopula-
tion (nT= 3). To avoid acidification of the hypoxic cultures, the medium was
regularly replaced with fresh media pre-equilibrated in hypoxia. For differentiation,
cells were grown as adherent cultures in 10× diluted Matrigel in original medium
depleted from bFGF and EGF and supplemented with 10% FBS and 10 ng ml−1
All-Trans Retinoic acid (ATRA, Sigma) for 14 days. Cells were re-adapted to
normoxic 3D sphere cultures for an additional 14 days in original culture media.
Experiments were repeated independently three times (nB= 3) with three technical
replicates per subpopulation (nT= 3).
Immunostaining. NCH644 spheres were embedded in Tissue-Tek® O.C.T.™
Compound (Sakura Finetek) and flashfrozen at −80 °C. Immunocytochemistry
was performed on 10 µm sections, fixed in 4% PFA for 10 min. Adherent cultures
were fixed directly in the plates. Fixed samples were blocked for 30 min in TBS
supplied with 0.1% Triton-X100 and 2% FBS and incubated with primary anti-
bodies (see Supplementary Table 3 for antibodies used) and 1 µg ml−1 DAPI
(Invitrogen). Secondary antibody staining was performed when needed. For image
acquisition, a Leica® DMI6000 B inverted microscope with a Leica® 350 FX camera
was used with its concordant Leica Application Suite® software.
Flow cytometry settings. Data acquisition was performed on a FACS AriaTM
SORP cytometer (BD Biosciences) fitted with a 640 nm (30 mW) red laser, a 355
nm (60 mW) UV laser, a 405 nm (50 mW) violet laser, a 488 nm (100 mW) blue
laser, and a 561 nm (50 mW) yellow/green laser. The Hoechst dye was excited by
the UV laser and fluorescence was collected in two channels: UV-1 450/50 band-
pass (BP) filter and UV-2′ 660/40 long-pass (LP) filter. An LP 635 nm dichroic
mirror was used to split the emission wavelengths. The instrument was calibrated
each time with Cytometer Setup&Tracking Beads (BD Bioscience). The Coefficient
of Variation of the instrument (% CV) was routinely examined before each
experiment. A 100 µm nozzle and window extension (WE) 3 were used for data
acquisition and sorting. Imaging flow cytometry was performed with an Image-
Stream imaging cytometer (Amnis) fitted with a 375 UV laser, a 488 blue laser, a
561 yellow-green laser, a 642 red laser, and a 785 nm infrared laser. Acquisition was
performed with the INSPIRE® software and analysis was performed using IDEAS®
image analysis software. Pictures were taken at ×60 magnification at low-speed
high-sensitivity mode.
Multicolor cell membrane phenotyping. Cell cultures were dissociated using
Accutase® (Sigma-Aldrich). Xenografts were dissociated with MACS Neural Tissue
Dissociation Kit (P) (Miltenyi) following the manufacturers’ instructions. Single
cells were resuspended in HBSS, 2% FBS, 10 mM HEPES buffer (100 µl per test).
Cells were incubated with the IR-LIVE/DEAD® Fixable Dead Cell Stains (Invi-
trogen; 1 µg ml−1) and appropriate preconjugated antibodies for 30 min at 4 °C in
the dark (Supplementary Table 3). For cell cycle analysis in viable cells, cells were
prestained with Hoechst 33342 (5 µg ml−1, Bisbenzimide, Ho342; Sigma) at 37 °C
before antibody staining37. Data acquisition was performed on a FACS AriaTM
SORP cytometer (BD Biosciences) and ImageStream imaging cytometer (Amnis).
Data acquisition and analysis were done for FACSAria with DIVA software (BD
Bioscience); and INSPIRE and IDEAS® for ImageStream. Histograms were pre-
pared with the FlowJo software.
Intracellular marker phenotyping and apoptosis test. Cell cultures were dis-
sociated using Accutase® (Sigma-Aldrich) Xenografts were dissociated with MACS
Neural Tissue Dissociation Kit (P) (Miltenyi) following the manufacturers’ instruc-
tions. Single cells were resuspended in HBSS, 2% FBS, 10mM HEPES buffer (100 µl
per test). Cells were incubated with the IR-LIVE/DEAD® Fixable Dead Cell Stains
(Invitrogen; 1 µg/ml) and appropriate preconjugated antibodies for 30min at 4 °C in
the dark (Supplementary Table 3). Cells were fixed with the BD CytofixTM solution
for 20min and permeabilised in the BD Perm/WashTM for 10min at RT. Cells were
incubated with appropriate preconjugated antibodies for 30min at 4 °C in the dark
(Supplementary Table 3). Data acquisition was performed on a FACS AriaTM SORP
cytometer (BD Biosciences). For apoptosis test cells were resuspended in 100 µl of
binding buffer (HBSS w/o Ca2+ /Mg2+ (Sigma-Aldrich), 2% FBS and 0.01M Hepes
pH 7,4, 0.14M NaCl (Sigma-Aldrich), and 2.5mM CaCl2 (Sigma-Aldrich)). Staining
with AnnexinV-APC (Immunotools) was performed for 30min at room temperature
in dark. Cells were subsequently washed with binding buffer and kept on ice until
analysis on flow cytometer. In total, 50 µgml−1 propidium iodide (PI) (Invitrogen)
was added 5min before data acquisition. The experiment was performed in three
biological replicates (nB= 3) with three technical replicates each (nT= 3). Statistical
differences were calculated using Student t-test with Bonferroni multiple-significance-
test correction for four comparisons.
Self-renewal test in vitro. Single cells from 16 subpopulations were FACS-sorted
to a 96-well plate (1 cell per well; one 96-well plate per subpopulation) and cultured
for 4 weeks in normoxia or 0.5% O2 hypoxia. Spheres derived from each sub-
population were collected (passage 1) and single viable cells were resorted and
plated as single cells (one 96-well plate per subpopulation, 1 cell per well).
Replating was done three times to reach four passages in total. Only spheres
> 40 µm were considered as a positive result for sphere forming capacity. Total
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sphere number and average sphere size (n= 20 per subpopulation if available) were
recorded at each passage before cell harvesting. Each subpopulation at each passage
was phenotyped as described above. FACS-sorted viable single cells from the bulk
cells were used as control. The experiment was repeated independently four times.
Significant differences in sphere number across populations and passages were
evaluated with the Kruskal–Wallis test. Significant differences in sphere size were
tested with mixed linear models with either subpopulation or passage as fixed-
effects and considering batch effect as random.
Proliferation and mulitpotency test. In total, 300 cells of each
NCH644 subpopulation were FACS-sorted to a 48-well plate and cultured for 20,
30, and 70 days in normoxia or 0.5% O2 hypoxia. At each time point, cells derived
from each subpopulation were phenotyped as described above. Total cell number
was recorded with the Countess® cell counter (Invitrogen) after 20 and 30 days of
culture to determine the proliferation rate. Doubling time was calculated as follows:




, where t1 and t2 represent time points. FACS-sorted
single viable cells from bulk were used as control. The experiment was repeated
independently four times (nB= 4) with three technical replicates per subpopulation
(nT= 3). Significant differences of doubling times were tested with mixed linear
models with subpopulation as fixed-effects and considering plate effects as random.
The proportion of each subpopulation was calculated as the percentage of viable
single cells. The column chart graphs show mean percentage of technical and
biological replicates. Error bars were omitted for visualization purposes. Alluvial
plots have been generated under R using the package alluvial available at https://
github.com/mbojan/alluvial. Significant differences between phenotypic states were
calculated with the Student’s t-test with Bonferroni’s multiple comparison test/
correction.
Mathematical modeling. Markov model principles: To quantify the transitions
between the 16 phenotypes we applied Markov chain modeling implemented in the
freely available R package CellTrans (http://github.com/tbuder/CellTrans)41. The
model is based on the assumptions that cell state alterations occur due to stochastic
cell state transitions only depending on the current state of the cell and possibly the
experimental environment (e.g., hypoxia) and that proliferation rates of the
involved phenotypes are approximately equal. Since all examined subpopulations
proliferated at a similar rate both in normoxia (Fig. 2c) and hypoxia (Fig. 3c), the
proliferation rates were neglected for the estimation of transition rates. In vitro
experiments were performed under two different environmental conditions (nor-
moxia, hypoxia) and transition rates were estimated separately for each condition.
In the absence of known data about inter-cellular interactions, these components
were omitted. Our modeling approach led to a Markov chain with a transition
matrix containing the probabilities of state transitions allowing to discriminate
frequent and non-frequent state transitions and identify hierarchical or non-
hierarchical transition behavior. If the underlying network is irreducible, each state
can transit directly or via intermediate steps into any other state. This behavior
implies that stochastic state transitions are non-hierarchical and therefore rever-
sible in a biological sense. In contrast, if the transition network has a tree structure,
it corresponds to a perfect hierarchy. Intermediate network structures are possible
as well, which imply some degree of hierarchy between transient states at the top of
the hierarchy and recurrent states at the bottom of the hierarchy. Moreover, on the
basis of the estimated transition matrix, it is possible to predict the composition of
the population in equilibrium by calculating the Markov chain stationary state. In
addition, the time from a specific initial composition until an approximate equi-
librium is reached can be estimated.
Construction of data matrices: Let wðtÞi;j denote the experimentally observed
mean proportion of phenotype j, j= 1,…,16, in the experiment starting with pure
subpopulations of phenotype i, i= 1,…,16, at time t. Then, one can construct a
phenotype proportion matrix at time t as follows.
WðtÞ ¼










Note that the phenotype proportion matrix describing the initial proportions is
the 16 × 16 identity matrix, i.e.
Wð0Þ ¼
1 0       0


















The transitions between the phenotypes were estimated as probabilities of state
transition per time-step of the underlying Markov chain. Importantly, the
implications of the model with respect to hierarchical structure, equilibrium
composition and relaxation time are highly independent of the choice of the time-
step length. Here, we choose a time-step length of 1 day. We obtained three
phenotype matrices from the experimental data in normoxia: W(20) after 20 days,
W(30) after 30 days, and W(70) after 70 days. In hypoxia we constructed only one
matrix, namely W(60) for the measurement after 60 days.
Estimation of the transition probabilities: Markov chain theory allows to
connect the initial phenotype proportion matrix with the phenotype matrix after n
time-steps with the equation W(0)Pn=W(n). This equation can be solved for the
underlying transition matrix P, i.e.






Hence, we obtained the three transition matrices P̂ð20Þ; bPð30Þ, and P̂ð70Þ in
normoxia which needed to be regularized in order to obtain stochastic matrices, see
ref. 41 for details. These matrices were averaged to obtain a final estimate for the
transition matrix P, i.e., P̂ ¼ P̂ 7ð ÞþP̂ð10ÞþP̂ 23ð Þ3 . In hypoxia, P ¼ P̂ð60Þ was used since
there was only one time point of measurement.
Krackhardt hierarchy: To estimate the degree of hierarchy of the estimated
transition matrixes from data obtained under different environmental conditions,
graph hierarchy introduced by Krackhardt was calculated68. The degree of
deviation from pure hierarchy, i.e., tree structure, is assessed by counting the
number of pairs that have reciprocated ties relative to the number of pairs where
there is not any tie, i.e., the proportion p of all tied pairs having reciprocated ties.
Krackhardt hierarchy is then defined as 1−p. A perfect hierarchy is characterized
by no reciprocated ties and exhibits a Krackhardt hierarchy of one. Calculations
were performed in R using hierarchy function with Krackhardt measure.
Marker dependency calculation: We investigated whether the cell state
transitions between positive and low/negative expression of one marker in
normoxia and hypoxia were dependent on the level of expression of the other
markers. For each marker, we distinguished two phenotypic states with respect to
positive and low/negative expression of this marker. In detail, we added the
percentage of all CSC-associated subpopulations with positive or low/negative
expression of that marker in the measured plasticity data for each time point of
measurement. This resulted in 2 × 2 cell state proportion matrixes per time point.
This coarse-grained data could be utilized to derive corresponding 2 × 2 cell state
transition matrixes and corresponding steady states by applying CellTrans41. The
steady states of these 2 × 2 cell state transition matrices could then be compared
with the fractions of the corresponding phenotype when considering all four
markers in the analysis. Therefore, percentage of subpopulations with the same
expression of a single marker were added to obtain the steady state proportion for
each individual marker. Nearly equal equilibrium proportions indicate
independent transitions whereas large differences indicate a dependency.
Calculations were performed for normoxic and hypoxic datasets.
Cell line-derived xenografts and in vivo tumor formation. GBM patient-derived
cultures were implanted intracranially to NOD/Scid mice (50,000 per mouse for
NCH644 and NCH421k, 300,000 cells for NCH660h and NCH601, n= 3) into the
right frontal cortex using a stereotactic device. Animals were sacrificed at the
appearance of neurological symptoms and weight loss. To test tumorigenicity
in vivo, 5000 cells of P2, P6, P11, and P15 subpopulations and original NCH644
cells were engrafted into nude mice directly after sort (n= 7 per group). Animals
were monitored daily and the following criteria were evaluated: (1) loss of more
than 10% of body weight, (2) exhibition of strong neurological signs (difficulty
ambulating or abnormal movement), (3) increased lordosis, or (4) swollen belly.
The criteria were scored as follows: 0= none, 1= early, 2= established, 3= severe
signs and animals were sacrificed when three criteria with grade 2 or one criterion
with grade 3 were reached. Kaplan–Meier survival curves, log-rank test for survival
analysis and IC50 were calculated with the GraphPad Prism5. Tumor developed in
xenografted mice were FACS phenotyped as described above.
Single cell RNA-Seq using Drop-Seq. To obtain a pure population of single viable
cells all GBM cultures were FACS-sorted (NCH644, NCH421k bulk cultures and
NCH644 subpopulations P2 and P6). For GBM PDOXs we have pre-selected
hCD90 positive tumor cells. FACS-sorted populations were collected in HBSS,
0.5% BSA at 4 °C. Prior to cell loading on the Drop-seq chips, the viability of cells
was verified and concentration was adjusted to ~150 cells μl−1 as optimal con-
centration to achieve single-cell encapsulation within each droplet of ~ 1 nl. All
samples analyzed had a cell viability > 95%.
Microfluidics devices were fabricated using a previously published design46.
Softlithography was performed using SU-8 2050 photoresist (MicroChem) on 4″
silicon substrate to obtain a feature aspect depth of 100 μm. After overnight
silanization (using Chlorotrimethylsilane, Sigma), the wafer masks were used for
microfluidics fabrication. Drop-seq chips were fabricated using silicon based
polymerization chemistry. Briefly, polydimethylsiloxane (PDMS) base and cross-
linker (Dow Corning) were mixed at a 10:1 ratio, mixed and degassed before
pouring onto the Drop-seq master template. PDMS was cured on the master
template, at 80 °C for 2 h. After incubation and cooling, PDMS slabs were cut and
the inlet/outlet ports were punched with 1.25-mm biopsy punchers (World
Precision Instruments). The PDMS monolith was plasma-bonded to a clean
microscopic glass slide using a Harrick plasma cleaner. Immediately after pairing
the plasma-treated surfaces of the PDMS monolith and the glass slide, flow
channels of the Drop-seq chip were subjected to a hydrophobicity treatment using
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1H,1H,2H,2H-Perfluorodecyltrichlorosilane (in 2% v/v in FC-40 oil; Alfa Aeser/
Sigma). After 5 min of treatment, excessive silane was blown through the inlet/
outlet ports. Chips were further incubated at 80 °C for 15 min.
Experiments followed the original Drop-seq protocol46 with minor changes.
Synthesized barcoded beads (Chemgenes Corp., USA) were co-encapsulated with
cells inside the droplets containing lysis reagents using an optimal bead
concentration of 200 beads μl−1 in Drop-seq Lysis buffer medium. Cellular mRNA
was captured on the beads via barcoded oligo (dT) handles synthesized on the
surface. For cell encapsulation, 2 ml of cell and bead suspensions were loaded into
3 ml syringes (BD), respectively. To keep beads in homogenous suspension a
micro-stirrer was used (VP scientific). The QX 200 carrier oil (Bio-Rad) used as
continuous phase in the droplet generation was loaded into a 20 ml syringe (BD).
For droplet generation, 3.6 and 13 ml h−1 were used in KD scientific Legato syringe
pumps for the dispersed and continuous phase flows, respectively. After
stabilization of droplet formation, the droplet suspension was collected into a 50 ml
Falcon tube. Collection of the emulsion was carried out until 1 µl of the single cell
suspension was dispensed. Droplet consistency and stability were evaluated by
bright-field microscopy using INCYTO C-Chip Disposable Hemacytometer (Fisher
Scientific). Bead occupancy within droplets was carefully monitored to avoid
multiple bead occupancy. The subsequent steps of droplet breakage, bead
harvesting, reverse transcription, and exonuclease treatment were carried out in
accordance to46. RT buffer contained 1× Maxima RT buffer, 4% Ficoll PM-400
(Sigma), 1 μM dNTPs (ThermoScientific), 1 Uml−1 Rnase Inhibitor (Lucigen), 2.5
μM Template Switch Oligo, and 10 Uml−1 Maxima H-RT (ThermoScientific). Post
Exo-I treatment, the bead counts were estimated using INCYTO C-Chip
Disposable Hemacytometer, and 10,000 beads were aliquoted in 0.2 ml Eppendorf
PCR tubes. PCR mix was dispensed in a volume of 50 μl using 1× Hifi HotStart
Readymix (Kapa Biosystems) and 0.8 mM Template-Switch-PCR primer. The
thermocycling program for the PCR amplification was modified for the final PCR
cycles by 95 °C (3 min), four cycles of 98 °C (20 s), 65 °C (45 s), 72 °C (3 min), 10
cycles of 98 °C (20 s), 67 °C (20 s), 72 °C (3 min) and followed by a final extension
step of 72 °C for 5 min. Post PCR amplification, libraries were purified with 0.6×
Agencourt AMPure XP beads (Beckman Coulter), in accordance with the
manufacturer’s protocol. Finally, the purified libraries were eluted in 20 μl RNAase/
DNAase-free molecular grade water. Quality and concentration of the sequencing
libraries were assessed using BioAnalyzer High Sensitivity Chip (Agilent
Technologies).
The 3′ end enriched cDNA libraries were prepared by tagmentation reaction of
600 pg cDNA library using the standard Nextera XT tagmentation kit (Illumina).
Reactions were performed according to the manufacturer’s instructions, except for
the 400 nM primer sets replaced by Primer 1 (AATGATACGGCGACCACCGAG
ATCTACACGCCTGTCCGCGG AAGCAGTGGTA TCAACGCAGAG T*A*C)
and Primer 2 (N703: CAAGCAGAAGACGGCATACGAGA TTTCTGCCTGTCT
CGTGGGCTCGG for the NCH644 subpopulation 6 and N709: CAAGCAGAAGA
CGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG for NCH644
subpopulation 2, NCH644 and NCH421k). The PCR amplification cycling
program used was 95 °C 30 s; 14 cycles of 95 °C (10 s), 55 °C (30 s), 72 °C (30 s)
followed by a final extension step of 72 °C (5 min). Libraries were purified twice to
reduce primers and short DNA fragments with 0.6× and 1× Agencourt AMPure
XP beads (Beckman Coulter), respectively, in accordance with the manufacturer’s
protocol. Finally, purified libraries were eluted in 15 μl molecular grade water.
Quality and quantity of the tagmented cDNA library was evaluated using
BioAnalyzer High Sensitivity DNA Chip. The average size of the tagmented
libraries prior to sequencing was between 400 and 700 bps.
Purified Drop-seq cDNA libraries were sequenced using Illumina NextSeq 500
with the recommended sequencing protocol except for 6 pM of custom primer
(GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC) applied for
priming of read 1. Paired end sequencing was performed with the read 1 of 20
bases (covering the random cell barcode 1–12 bases) and the rest 13–20 bases of
random unique molecular identifier (UMI) and for read 2 the 50 bases of the genes.
The FASTQ files were assembled from the raw BCL files using Illumina’s
bcl2fastq converter and ran through the FASTQC codes [Babraham bioinformatics;
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/] to check for
consistency in library qualities. The monitored quality assessment parameters were
(a) quality per base sequence (especially for the read 2 of the gene), (b) per base N
content, (c) per base sequence content, and (d) overrepresented sequences.
Libraries that showed significant deviation were re-sequenced. The FASTQ files
were then merged and converted to binaries using PICARD’s fastqtosam algorithm.
The sequencing reads were converted to a digital gene expression matrix (DGE)
using the Drop-seq bioinformatics pipeline46. To normalize for the transcript
loading between the beads, the averaged normalized expression levels (log2(TPM
+1)) were calculated. Beads without cellular mRNAs were identified by using a
cumulative function of the total number of transcripts per barcode and empirical
thresholding on the resulting “knee plot”. To filter poor quality reads and cells with
low transcript content, only cells with at least 1500 expressed genes and genes at
least expressed in 20 cells were considered for further analysis. The average number
of UMI-collapsed transcripts per cell was 5970 corresponding to the 2430 genes
detected per cell on average.
To remove batch effect, we used independent component analysis ICA (R
fastICA package) decomposing the original expression matrix into a product of
statistically independent signals and weight matrices: Xnm= Snk ×Mkm, where Xnm
is the log-transformed count matrix for n genes and m cells, Snk is a matrix of k
independent components and Mkm is the weight matrix for each component
over m cells. Stability of the ICA decomposing was tested by 100 runs of ICA. The
log-transformed count matrix was decomposed using eight independent
components. The optimal number of components was selected by minimizing the
correlation between rows of weight matrix. We observed that the weight of
component #7 was strongly linked to the experimental batch. In accordance with69,
this component was suppressed by setting its weight (M7,i, where i= 1.. m) to 0,
and the normalized data were recovered by matrix multiplication of the
components by their weights.
Estimation of the highly variable genes and principal component reduction and
tSNE dimensionality reduction was implemented using SEURAT R package
(http://satijalab.org/seurat/) or the R package Rtsne with an initial PCA, a
perplexity of 40 and a learning rate of 200 (5000 iterations) (https://github.com/
jkrijthe/Rtsne). For reproducibility with the original algorithm, the theta value was
set to zero.
The correlation coefficient was calculated between each cell after filtering using
the Pearson method; the mean value is represented for each group/subpopulation/
fraction. Differential expression analysis was performed using DESeq2 package of
R. Here the raw integer counts were used for consistency with the algorithm
requirements. Centering of the gene expression value was performed by obtaining
the relative expression levels, by subtracting the average expression value
(log2(TPM+1)) of each gene from all the cells of the gene expression matrix. For
cell cycle analysis we have applied two prominent gene expression programs of the
G1/S (100 genes) and G2/M phases (133 genes), shown to overlap in the two
programs46. Due to the sparsity of the single-cell RNA-seq data, the expression
data for each cell cycle phase were refined by evaluating the correlation data
between each of the genes in the scRNAseq data with the average gene expression
values of all the genes involved in the respective cell cycle program (G1/S & G2/M),
and including all the genes with high correlation value (R2 > 0.3; Pval < 0.05,
Spearman’s correlation). The biaxial plot of G1/S and G2/M programs illustrated
in the Fig. 5c is the average score of all the genes involved in the respective cell
cycle programs. Figure 5c further represents the expression value of different genes
of interest by mapping the expression value onto the respective cells.
Genome-wide microarray expression analysis. Gene expression profiles of GBM
cells were analyzed after 16 h and 7 days of culture in severe hypoxia (0.1–0.5% O2)
and compared with normoxic cells44,45. For TMZ treated cells, a high-dose (500
µM) short-term (24 h) treatment was applied. Total RNA was extracted using
QIAGEN® RNeasy Mini Kit (Qiagen) or Trizol, according to the manufacturer’s
protocols and processed (250 ng) using the Affymetrix WT Expression kit before
being hybridized to GeneChip® Human Gene 1.0ST Arrays or GeneChip® Human
Transcriptome Arrays 2.0 (Affymetrix) (protocol P/N 702808 Rev.6). CEL files
containing hybridization raw signal intensities were imported into the Partek GS
software for further statistical analysis. R statistical environment was used for
hierarchical clustering, principal component analysis and for empirical Bayesian
statistics (LIMMA, R/Bioconductor).
Statistical tests. The statistical approaches have been chosen based on the data
type and measurements across the manuscript. Statistical tests are described in each
paragraph above corresponding to the associated experimental procedures.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Gene expression profiles across glioma patients were investigated using publicly available
datasets: (i) GlioVis data portal65 http://gliovis.bioinfo.cnio.es/; (ii) Cbioportal66 http://
www.cbioportal.org/; and (iii) RecurR http://recur.bioinfo.cnio.es/. DNA microarray data
are available in the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) under
the accession number E-MTAB-3085. The scRNA-seq data are available in the Gene
Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo) under the accession number
GSE128195. Scripts supporting mathematical modeling are available in the R package
CellTrans (http://github.com/tbuder/CellTrans)41. Remaining datasets supporting the
findings are available from the corresponding author on reasonable request.
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